Jupiter Wellness, Inc. (NASDAQ: JUPW) to Present JW-300 Topical Burn Treatment at SCALE 2022 Aesthetic Medicine, Plastic Surgery and Medical Dermatology Conference

Strong points:

– Developer of CBD-based treatments for multiple skincare applications.

– New e-commerce and marketing team with experienced industry veterans.

– Exclusive worldwide rights to patented anti-shark technologies.

– A new combined treatment with cannabidiol and aspartame significantly reduces the ISGA score in atopic dermatitis.

– Exclusive worldwide rights to unique formulas addressing Jellyfish and Man O’ War Stings, Sea Lice and Swimmer’s Itch with 4 patents pending.

– Double-blind, placebo-controlled clinical trial of JW-200 for the treatment of actinic keratosis.

– Executive Chairman of Next Frontier, merger partner, interviewed by Benzinga.

– Approval by JUPW’s Board of Directors of a $5.0 million share buyback program.

JUPW will present data from Jupiter’s JW-300, a topical cannabidiol treatment for first-degree burns, at the SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology conference being held May 11-15, 2022 in Nashville, Tennessee.

In a clinical trial of 36 patients, a controlled area of ​​skin was exposed to UV irradiation. The percentage of subjects with burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received placebo lotion. The percentage of burn subjects in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the mean erythema score was 0.388 after radiotherapy versus 0.722 in the placebo arm (n=18).

Dr. Glynn Wilson, Jupiter Wellness Chief Scientist, said: “These statistically significant results demonstrate the potential of JW-300 as a prescription or over-the-counter topical cream to help prevent sunburn and its consequences. more harmful such as skin cancer. We look forward to presenting this important data to SCALE’s leading dermatology and aesthetic medicine physicians. »

Jupiter CEO Brian John added, “JW-300 complements our current over-the-counter skincare products, including CaniSun™ as well as our prescription product Photocil™, serving a large market that needs solutions. more efficient.

JUPW recently announced that it has entered into an asset purchase agreement with Ascent Clinical Research, Inc. whereby it has acquired certain clinical assets, including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets.

About JUPW:

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) therapeutic and medical wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics addresses indications such as eczema, burns, herpetic cold sores, and skin cancer. JUPW generates revenue from a growing line of exclusive over-the-counter skincare products, including its flagship CaniSun™ sunscreen and other wellness brands sold through its strong distribution platform.

Over the past two years, JUPW has built a portfolio of award-winning wellness brands including CaniSun, Jack, Wellness 1937, Black Belt and Felix Ambrosia, as well as prescription therapeutics such as Photosil that have been featured in numerous media, including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed and Forbes.

JUPW will launch CaniSun for Shark Defense Sunscreen with Patented Shark Repellents:

Exclusive worldwide rights to patented anti-shark technologies for the sun and skin market licensed from Shark Defense Technologies.

Watch the Discovery Channel videos on anti-shark technology here: https://youtu.be/PM0YTlbx1qg

On April 7, JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the company’s line of reef-friendly sunscreens. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher in chemical, electrochemical and magnetic shark repellents, JUPW owns the exclusive worldwide rights to the patents, formulas and production methods of the shark repellent technologies. for use in sunscreen and skin care products.

A new treatment (JW-100) significantly reduces the ISGA score in atopic dermatitis: results of a randomized, double-blind, placebo-controlled interventional study:

On April 6, JUPW announced the publication of the results of a clinical study to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic. Dermatology, Vol. 21, number 4, April 2022, pages: 1647-1650.

JUPW launches NoStingz Jellyfish protective sunscreen backed by a patent-pending formula in the $13 billion sunscreen market:

Exclusive worldwide rights to unique formulas treating jellyfish and man-of-war stings, sea lice and swimmer’s itch with 4 patents pending.

On April 5, JUPW announced the launch of NoStingz, an exclusive line of sunscreens designed to protect against jellyfish and man-of-war stings, sea lice and swimmer’s itch while continuing to protect the skin. ocean lovers against UVA/UVB in a range of SPF. JUPW has signed a licensing agreement with Shark Defense Technologies for exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds, including 4 patents pending. The agreement provides for future collaboration to develop and refine additional formulas.

To learn more about the JUPW NoStingz product or to purchase, visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/

Approval by the JUPW Board of Directors of a $5.0 million share buyback program:

On January 25, JUPW announced that its board of directors had approved a $5.0 million stock repurchase program that expires on June 30, 2022. Under the stock repurchase program, common stock of JUPW may be repurchased periodically on the open market or in privately negotiated transactions.

For more information about Jupiter Wellness, Inc. (JUPW), visit www.jupiterwellnessinc.com.

Products mentioned are THC-free and/or Farm Bill 2018 compliant.

WARNING: This article is for informational purposes only and does not constitute a recommendation to buy or sell stocks.

Media Contact
Company Name: Jupiter Wellness, Inc.
Contact person: Brian John, CEO
E-mail: Send an email
Call: (561)244-7100
Country: United States
Website: https://jupiterwellness.com/

Comments are closed.